The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.
Jakob Vasehus Schou
No relevant relationships to disclose
Klaus Kaae Andersen
No relevant relationships to disclose
Benny Vittrup Jensen
Consultant or Advisory Role - Merck Serono
Research Funding - Merck Serono
Dorte Lisbet Nielsen
No relevant relationships to disclose
Estrid V. Høgdall
No relevant relationships to disclose
Julia S. Johansen
No relevant relationships to disclose